The value of chest computed tomography in evaluating lung cancer in a lobe affected by stable pulmonary tuberculosis in middle-aged and elderly patients: A preliminary study

Kui Long1,2, Hui Zhou1,3*, Yajuan Li1, Liang Liu1,2 and Jiahui Cai4

1Department of Radiology, Xiangya Hospital, Central South University, Changsha, China, 2Department of Radiology, Xiangya Changde Hospital, Changde, China, 3National Clinical Research Center for Geriatric Disorders, Xiangya Hospital Central South University, Changsha, China, 4Department of Radiology, Qingyuan people’s Hospital, Qingyuan, China

Introduction: Lung cancer can be masked by coexisting stable tuberculosis lesions, which may result in delayed lung cancer diagnosis and treatment. Information about pulmonary tuberculosis patients who are at high-risk of developing lung cancer is scarce. We aimed to examine the value of chest computed tomography (CT) in evaluating lung cancer in a lobe affected by stable pulmonary tuberculosis in middle-aged and elderly patients.

Methods: In this single-centered, retrospective, observational study, we enrolled 41 middle-aged and elderly patients with pulmonary tuberculosis who developed lung cancer in the same lobe from January 30, 2011 to December 30, 2020. Comparisons of the clinical and chest CT data were made with age-matched and sex-matched control groups of patients with stable pulmonary tuberculosis but no lung cancer diagnosis (n = 38).

Results: Seventeen patients in the lung cancer group (41%) were initially misdiagnosed. Compared to lesions in the control group, lesions in the lung cancer group were significantly more likely to demonstrate the following CT features: large size, vessel convergence, lobulation, spiculation, spinous protuberance, bronchial obstruction or stenosis, vacuolation, ground-glass opacification, heterogeneous or homogeneous enhancement, and gradual increase in size. Nodular enlargement showed the best diagnostic performance in the diagnosis of lung cancer in a lobe affected by stable pulmonary tuberculosis (area under the receiver operating characteristic curve = 0.974; P <0.001; accuracy = 98.2%; sensitivity =94.7%; specificity = 100%).

Conclusion: Chest CT might play an important role in early diagnosis of lung cancer in a lobe affected by tuberculosis. Regular CT re-examination is
Introduction

Although the current coronavirus disease 2019 (COVID-19) pandemic has caused considerable illness and death around the world since early 2020, the impact of tuberculosis has been even greater. Tuberculosis remains a widespread disease in many developing countries, including China, and more than 1.4 million people worldwide die of tuberculosis every year (1). Among all cancers in China, lung cancer has the highest prevalence and causes the greatest number of deaths (2). In addition, studies have shown that lung cancer is more likely to develop in pulmonary tuberculosis patients than the general population (3, 4). Lung cancer can be masked by coexisting stable tuberculosis lesions in the same lobe, which may result in delayed lung cancer diagnosis and treatment as well as worse patient outcomes. In this retrospective case-cohort study, we analyzed and compared clinical and computed tomography (CT) data of all consecutive patients with pulmonary tuberculosis who developed lung cancer with age- and sex-matched controls (pulmonary tuberculosis patient without lung cancer) to investigate CT predictors of lung cancer. Our aim was to examine the value of CT screening in pulmonary tuberculosis patients who are at high-risk of developing lung cancer.

Materials and methods

Study design and patients

The clinical and chest CT data of 759 consecutive middle-aged and elderly patients with stable pulmonary tuberculosis diagnosed in our hospital from January 30, 2011 to December 30, 2020 were analyzed retrospectively. The study was approved by our Medical Ethics Committee (No. 202012230). Stable tuberculosis was identified by comprehensive analysis of clinical manifestations, treatment history and imaging (5). The presence and localization of pulmonary tuberculosis was determined on chest CT by two radiologists (with 5 and 19 years of chest CT interpretation experience, respectively) who reached a consensus regarding tuberculous lesion location and activity. All the included patients were followed up for more than 2 years and diagnosed with lung cancer in the same lobe of tuberculosis. 718 patients (95%) were considered ineligible, including two patients who had motion artifact of chest CT. 41 patients with lung cancer (5%) occurrence in a lobe affected by tuberculosis were included in this study (Figure 1). Histopathological confirmation of lung cancer (including secondary scar carcinoma and primary cancer) was obtained by percutaneous biopsy, bronchoscopic biopsy, or surgical resection. In the lung cancer group, the pathological types were as follows: adenocarcinoma, 26 cases; squamous cell carcinoma, 8 cases; unclassified non-small cell lung cancer, 4 cases; small cell lung cancer, 2 cases; and sarcomatoid carcinoma, 1 case. Comparisons were made with age-matched and sex-matched control group of patients with stable pulmonary tuberculosis but no lung cancer diagnosis (n = 38). The detailed information of control group was listed in Table 1. 22% of patients of lung cancer group (9/41) underwent PET/CT after finding the suspected malignant lesions by CT before surgery, while none of the control group underwent PET/CT.

![Study flow diagram CT, computed tomography.](image-url)
CT and imaging interpretation

CT was performed using a 256-row (Revolution CT; General Electric, Boston, MA, USA) or 64-layer dual source (SOMATOM Definition; Siemens, Munich, Germany) scanner. Patients were scanned in the supine position from the top of the lung to the diaphragm during breath holding. The SOMATOM Definition main technical parameters were: 100kV, 150 mA, pitch value 0.6–0.9, and scanning layer thickness 1 mm. The Revolution CT main technical parameters were: 120 kV, 80–350 mA, pitch value 0.992, scanning layer thickness 0.625 mm, reconstruction thickness 1 mm, reconstruction interval 1 mm, reconstruction matrix 512 × 512. Some patients underwent a contrast-enhanced examination with a delay of 60 seconds. Non-ionic contrast medium (Ultravist; Bayer, Leverkusen, Germany) with iodine concentration of 300 mg/mL was injected into an antecubital vein at a rate of 2.0 mL/s for a patient dose of 1.5 mg/kg.

All the first chest CT scans after the diagnosis of stable pulmonary tuberculosis were subject to blind review by two radiologists mentioned above in consensus. If the results were inconsistent, a consensus was reached after negotiation. All images were viewed on both the lung (width, 1200 HU; level, −600 HU) and mediastinal (width, 350 HU; level, 40 HU) settings on the picture archiving and communication system. The following tuberculosis lesion characteristics (6, 7) were recorded: A) morphological characteristics (length and diameter of nodules, vessel convergence, lobulations, spiculations, spiculation protuberance, bronchial stenosis or occlusion, obstructive pneumonia, obstructive atelectasis, necrosis, cavitation, vacuolation, calcification, presence of ground glass nodules and/or satellite foci); B) non-enhanced CT value and enhancement characteristics of tuberculosis nodules, including minimum CT value, average CT value, degree of nodular enhancement, and enhancement pattern; C) characteristics of enlarged mediastinal lymph nodes; D) pleural thickening; E) lesion size on follow-up examination. To obtain the proper CT value (8), the region of interest (ROI) of target lesion was cautiously drawn freehand around the peripheral boundary of the lesion to exclude surrounding air, blood vessels, and atelectatic lung. The ROI was drawn as large as possible to minimize influences of noise and the partial volume effect, and calcified areas were avoided as far as possible. The selected sections of measurement remained the same before and after enhancement. If there was substantial artifact from respiration or cardiac motion, the image was eliminated from data analysis. The definition of nodular enlargement is an increase in size of > 1.5 mm (> 2 mm³) measured at baseline and during follow-up based on Lung-RADS Version 1.1 (9).

Statistical analysis

Statistical analyses were performed using SPSS software version 23.0 (IBM Corp., Armonk, NY, USA). Categorical variables are presented as numbers with frequency and were compared using the χ² test or Fisher’s exact test. Continuous variables are presented as means with standard deviation and were compared using one-way analysis of variance or the independent-samples t-test as appropriate. Receiver operating characteristic (ROC) curves were created using MedCalc software version 18.2.1 (MedCalc Software, Ltd., Ostend, Belgium) and the area under the curve (AUC) was calculated. The cut-off value was obtained using the Youden index method. Sensitivity, specificity, and accuracy were calculated. P < 0.05 was considered significant.

### Table 1: Clinical data of patients with lung cancer occurrence in a lobe affected by tuberculosis and control group.

| Project                             | Normal range | Lung cancer group (n = 41) | Control group (n = 38) | t/χ² value | P value |
|-------------------------------------|--------------|----------------------------|------------------------|------------|---------|
| Age (years)                         | 66.2 ± 8.4   | 65.8 ± 12.0                |                        | 0.161      | 0.872   |
| Sex Male/Female                     | 34 (83%)/7 (17%) | 27 (71%)/11 (29%)          |                        | 1.561      | 0.212   |
| Years of tuberculosis              | 16.9 ± 15.3  | 11.9 ± 11.9                |                        | 1.115      | 0.272   |
| Smoking                             | 26 (63%)     | 19 (50%)                   |                        | 1.429      | 0.232   |
| Diabetes                            | 3 (7%)       | 5 (13%)                    |                        | 0.730      | 0.393   |
| CEA, elevated ≤ 5.0 ng/mL           | 13 (13/34, 38%) | 0 (0/9, 0%)                |                        | 4.325      | 0.038   |
|NSE, elevated ≤ 13.0 ng/mL           | 1 (1/33, 3%)  | 1 (1/22, 5%)               |                        | 0.085      | 0.771   |
|CA-125, elevated ≤ 35.0 KU/L         | 4 (4/23, 17%) | 0 (0/14, 0%)               |                        | 2.539      | 0.111   |
|SCC, elevated ≤ 1.2 ng/mL            | 1 (1/19, 5%)  | 0 (0/9, 0%)                |                        | 0.474      | 0.491   |
| NSCLC-21-1, elevated ≤ 3.0 ng/mL    | 3 (3/18, 17%) | 0 (0/9, 0%)                |                        | 1.625      | 0.238   |
|CK19, elevated ≤ 4.0 mU/ml           | 4 (4/33, 12%) | 1 (1/15, 6%)               |                        | 0.322      | 0.570   |
|Tuberculosis antibody, positive      | 4 (4/27, 14%) | 3 (3/15, 18%)              |                        | 0.229      | 0.633   |
|Tuberculin skin test, positive       | 18 (18/33, 55%) | 13 (13/22, 59%)           |                        | 0.109      | 0.741   |
| TSPOT, positive                     | 20 (20/28, 71%) | 10 (10/12, 83%)           |                        | 0.619      | 0.431   |
Results

Clinical characteristics and laboratory findings

Patient clinical characteristics and laboratory findings are shown in Table 1. Serum CEA concentration was significantly higher in the lung cancer group than the control group (P = 0.038). Patient age; sex; smoking; diabetes; years of tuberculosis; concentrations of NSE, NSCLC-21-1, CA 125, SCC antigen, and CK-19; and tuberculosis antibody and T-SPOT testing did not significantly differ between the two groups.

CT characteristics

CT characteristics are shown in Table 2. The typical CT manifestations of three pulmonary tuberculosis patients who developed lung cancer were shown in Figure 2. Among the 41 patients with lung cancer, 17 (41%) were initially misdiagnosed as follows: failure to observe new nodules because of masking by coexisting stable tuberculosis lesions (n = 6), misdiagnosis as reactivation of tuberculosis (n = 5), failure to observe because of lesion subtleness (n = 4), and misdiagnosis as a common infection (n = 2). Compared to lesions in the control group, lesions in the lung cancer group were significantly more likely to demonstrate the following CT features which were defined as high-risk CT manifestations: large size, vessel convergence, lobulation, spiculation, spinous protuberance, bronchial obstruction or stenosis, vacuolation, ground-glass opacification, heterogeneous or homogeneous enhancement, and gradual increase in size (Figure 2). However, the control group was more likely to have a satellite lesion and had significantly higher minimum and mean CT values.

Diagnostic efficiency

As shown in Table 3, nodular enlargement showed the best diagnostic performance in the diagnosis of lung cancer in a lobe affected by tuberculosis (AUC = 0.974; P < 0.001; accuracy = 98.2%; sensitivity = 94.7%; specificity = 100%). Mean nodule CT value (49 HU) also showed adequate diagnostic performance (AUC = 0.758; P < 0.001; accuracy = 87.3%; sensitivity = 90.2%; specificity = 68.4%). The comparison of clinical and CT characteristics of patients with or without nodular enlargement and patients with high or low CT value (cut-off = 49 HU) are provided in the Online Appendix. Other clinical and CT features showed insufficient diagnostic performance (AUC <0.70).

Discussion

At present many clinicians have insufficient understanding of lung cancer affected by stable pulmonary tuberculosis, so the CT re-examination of patients with stable pulmonary tuberculosis is mainly carried out according to the consensus and guidelines of tuberculosis for evaluation of treatment response instead of low-dose CT (LDCT) guidelines for lung cancer screening (9, 12). At the same time, many tuberculosis patients did not have regular CT re-examination according to the clinician’s recommendation because they had no symptoms of tuberculosis and wanted to save cost. These reasons lead to the unequal interval of CT re-examination and frequent delays in the diagnosis of lung cancer. Among the 41 lung cancer patients with stable pulmonary tuberculosis in our study, 41% (17/41) were initially misdiagnosed. The main reason for these misdiagnoses may have been failure to observe new nodules because of masking by stable tuberculosis lesions. Since tuberculosis can also manifest as pulmonary nodules, early diagnosis of lung cancer can be difficult, which can delay treatment and affect patient prognosis (13).

CEA is a non-specific tumor marker which cannot be used as a diagnostic marker for lung cancer (14). It is mainly used for the observation of the effect of operation and chemotherapy, and can also be used for the prognostic evaluation of lung cancer patients (14). However, the obvious increase or continuous increase of CEA level should be paid more attention to in clinic (14). Adenocarcinoma was the most common pathological type in our lung cancer group (68%), which was similar to earlier studies (15, 16). Meanwhile, adenocarcinoma is the most common type of lung cancer with elevated CEA levels, which may explain the higher CEA levels in our group of lung cancer patients than in the control group. A Positive result of TSPOT shows the presence of Mycobacterium tuberculosis infection including active and latent tuberculosis infection (LTBI), which are more specific than the tuberculin skin test (TST) for diagnosis of LTBI (17). We found that 71% of patients in the lung cancer group were TSPOT positive, but the difference was not statistically significant compared with the control group. Similar results were obtained from the TST, indicating that there were other causes besides tuberculosis involved in lung cancer occurrence of tuberculosis patients. A previous population cohort study has found that 1/4 of newly diagnosed lung cancer patients have LTBI, and the tumors are mostly distributed in the location of tuberculosis infection (18). The coexistence of tuberculosis with bronchogenic carcinomas was detected in 30.2% of necropsy cases of bronchogenic carcinomas (19), while the incidence of tuberculosis amongst the general autopsies performed in the same department does not exceed 7-8%. The main pathological type of lung cancer associated with scarring is adenocarcinoma
and similar pathological findings were obtained in our study. Previous studies have reported that the risk of lung cancer is higher in tuberculosis patients than in those without tuberculosis (18, 21, 22). Chronic inflammatory stimulation, immune abnormalities, and gene mutations caused by tuberculosis infection and anti-tuberculosis drugs may be associated to the occurrence of lung cancer. Firstly, inflammation and pulmonary fibrosis caused by tuberculosis may lead to genetic damage that increases the risk of lung cancer (23–25). Secondly, tuberculosis may weaken the immune system and promote tumorigenesis (15). Thirdly, scar tissue may lead to atypical metaplasia and early peripheral pulmonary carcinoma can originate from terminal bronchioles around the scar (20). Fourthly, isoniazid was included in the list of Group 3

| Project                                      | Lung cancer group (n = 41) | Control group (n = 38) | $t$/$\chi^2$ value | $P$ value |
|----------------------------------------------|----------------------------|------------------------|-------------------|-----------|
| Nodular diameter (mm)                        | 26.5 ± 17.3                | 17.0 ± 12.1            | 2.828             | 0.006     |
| Vessel convergence                           | 24 (59%)                   | 9 (24%)                | 9.724             | 0.002     |
| Lobulations                                  | 33 (80%)                   | 18 (47%)               | 9.335             | 0.002     |
| Spiculations                                 |                            |                        |                   |           |
| Long spiculations (length < 5 mm)            | 12 (29%)                   | 10 (26%)               | 10.909            | 0.012     |
| Short spiculations (length ≥ 5 mm)           | 14 (34%)                   | 4 (11%)                | 6.676             | 0.010     |
| Long + Short spiculations                    | 2 (5%)                     | 0 (0%)                 | 1.667             | 0.197     |
| Spiculation protuberance                     | 16 (39%)                   | 5 (13%)                | 12.103            | < 0.001   |
| Bronchial obstruction                        | 19 (46%)                   | 4 (11%)                | 10.795            | 0.001     |
| Bronchial stenosis                           | 18 (44%)                   | 4 (11%)                | 1.878             | 0.171     |
| Necrosis in nodule                           | 4 (10%)                    | 1 (3%)                 | 7.028             | 0.008     |
| Calcification in nodule                      | 7 (17%)                    | 0 (0%)                 | 4.885             | 0.027     |
| Ground glass opacification                   | 18 (44%)                   | 25 (66%)               | 3.761             | 0.053     |
| Degree of enhancement                        | 5 (12%)                    | 0 (0%)                 |                   |           |
| No enhancement                               | 3 (3/32, 9%)               | 5 (5/12, 42%)          | 4.938             | 0.373     |
| Mild enhancement                             | 10 (10/32, 31%)            | 4 (4/12, 33%)          |                   |           |
| Moderate enhancement                         | 8 (8/32, 25%)              | 1 (1/12, 8%)           |                   |           |
| High enhancement                             | 11 (11/32, 34%)            | 2 (2/12, 17%)          |                   |           |
| No enhancement                               | 3 (3/32, 9%)               | 5 (5/12, 42%)          | 13.120            | 0.004     |
| Heterogeneous enhancement                    | 14 (14/32, 44%)            | 2 (2/12, 17%)          |                   |           |
| Homogeneous enhancement                      | 14 (14/32, 44%)            | 2 (2/12, 17%)          |                   |           |
| Ring-like enhancement                        | 1 (1/32, 3%)               | 3 (3/12, 25%)          |                   |           |
| Minimum CT value of nodule (HU)              | -40.0 ± 155.2              | 51.6 ± 202.1           | 2.247             | 0.028     |
| Mean CT value of nodule (HU)                 | -14.9 ± 135.2              | 165.7 ± 312.8          | 3.286             | 0.002     |
| Obstructive pneumonia                        | 4 (4/41, 10%)              | 2 (2/38, 5%)           | 0.560             | 0.454     |
| Obstructive atelectasis                      | 2 (2/41, 5%)               | 1 (1/38, 3%)           | 0.269             | 0.604     |
| Satellite lesions                            | 11 (11/41, 27%)            | 25 (25/38, 66%)        | 11.916            | <0.001    |
| Mediastinal lymphadenectomy                   | 19 (19/41, 46%)            | 15 (15/38, 39%)        | 0.722             | 0.395     |
| Lymph node enhancement                       |                            |                        |                   |           |
| No enhancement                               | 9 (9/32, 28%)              | 4 (4/12, 33%)          | 1.215             | 0.749     |
| Homogeneous enhancement                      | 21 (21/32, 66%)            | 8 (8/12, 67%)          |                   |           |
| Ring-like enhancement                        | 2 (2/32, 6%)               | 0 (0/12, 0%)           |                   |           |
| Pleural thickening                           |                            |                        |                   |           |
| Nodular thickening                           | 1 (1/41, 2%)               | 2 (2/38, 5%)           | 2.439             | 0.486     |
| Diffuse thickening                           | 1 (1/41, 2%)               | 0 (0/38, 0%)           |                   |           |
| Uneven thickening                            | 0 (0/41, 0%)               | 1 (1/38, 3%)           |                   |           |
| No thickening                                | 39 (39/41, 96%)            | 35 (35/38, 92%)        |                   |           |
| Enlarged nodule at follow-up                 | 37 (37/39, 95%)            | 0 (0/38, 0%)           | 70.485            | < 0.001   |
carcinogens by the international agency for research on cancer (IARC) of the World Health Organization, but more in-depth research is needed on whether anti-tuberculosis drugs can cause lung cancer. At the same time, detailed studies of molecular mechanism of tuberculosis infection in promoting lung cancer, as well as, for collection of more epidemiologic data are necessary.

It is not easy to distinguish lung cancer complicating tuberculosis from stable tuberculosis alone on CT. In this study, frequency of vessel convergence, lobulation, spiculation, and spinous protuberance was significantly higher in the lung cancer group than the control group and intranodular vacuoles were found only in the lung cancer group. These findings are considered classical CT features of peripheral lung cancer (26–28) and consistent with previous studies (31). Mean non-enhanced CT attenuation values were noticeably higher in lesions with a CT attenuation value lower than 49 HU. Our study also found that lung cancer nodules mainly enhanced heterogeneously or homogeneously, while tuberculosis nodules did not enhance or exhibited ring-like enhancement, which is consistent with previous studies (31). Mean non-enhanced CT attenuation and enhancement patterns of nodules should be considered together when attempting to discover lung cancer in patients with stable pulmonary tuberculosis.

Many clinical guidelines recommend FDG PET/CT for the evaluation of noncalcified pulmonary nodules ≥8 mm detected during low dose computed tomography (LDCT) lung cancer screening, and the use of FDG PET for the evaluation of ground-glass opacities was discouraged (9, 12, 32). In our case series, only 9(22%) patients underwent PET/CT, while none of the control group underwent PET/CT. It is noteworthy that all the patients went for PET/CT because the suspected malignant lesions found by CT. In pulmonary tuberculosis, inflammatory cells typically demonstrate increased ¹⁸F-FDG uptake, and areas of active tuberculosis can be differentiated

| Index                             | AUC (95%CI)          | P value | Optimal cut-off | Accuracy (%) | Sensitivity (%) | Specificity (%) |
|-----------------------------------|----------------------|---------|----------------|--------------|-----------------|-----------------|
| Elevated CEA                      | 0.691 (0.530-0.824)  | < 0.001 |                | 50.0         | 38.2            | 100             |
| Nodular diameter                  | 0.677 (0.563-0.778)  | < 0.001 | 23.1 (mm)      | 41.8         | 58.5            | 81.6            |
| Minimum CT value of nodule        | 0.614 (0.498-0.721)  | 0.084   | 28.8 (HU)      | 63.3         | 87.8            | 42.1            |
| Mean CT value of nodule           | 0.758 (0.648-0.847)  | < 0.001 | 49 (HU)        | 87.3         | 90.2            | 68.4            |
| Vessel convergence                | 0.674 (0.560-0.775)  | < 0.001 |                | 67.1         | 58.5            | 76.3            |
| Lobulations                       | 0.666 (0.551-0.768)  | 0.001   |                | 67.1         | 80.5            | 52.6            |
| Spiculations                      | 0.696 (0.582-0.794)  | < 0.001 |                | 68.3         | 63.2            |                |
| Spiculation protuberence          | 0.629 (0.513-0.735)  | 0.007   |                | 62.0         | 39.0            | 86.8            |
| Bronchial obstruction             | 0.679 (0.565-0.780)  | < 0.001 |                | 67.1         | 46.3            | 89.5            |
| Bronchial stenosis                | 0.667 (0.552-0.769)  | < 0.001 |                | 65.8         | 43.9            | 89.5            |
| Vacuolation in nodule             | 0.573 (0.457-0.684)  | 0.009   |                | 59.0         | 17.1            | 100             |
| Ground glass opacification        | 0.561 (0.445-0.673)  | 0.018   |                | 54.4         | 12.2            | 100             |
| Enhancement patterns              | 0.557 (0.400-0.707)  | 0.640   |                | 77.3         | 90.6            | 41.7            |
| Satellite lesions                 | 0.695 (0.581-0.793)  | < 0.001 |                | 30.4         | 26.8            | 34.2            |
| Enlarged nodule at follow-up      | 0.974 (0.892-0.998)  | < 0.001 |                | 98.2         | 94.7            | 100             |
However, standardized uptake value measurements are high in both tuberculosis and malignant lesions, with significant overlap that limits their usefulness (33, 34). As the differentiation of malignant lesions versus tuberculosis involvement is problematic and also the high radiation dose and high cost of PET/CT, it may be not suitable as a basic screening method for lung cancer in patients with tuberculosis.

This study has several limitations. First, it was retrospective in design, conducted in a single center, and had a sample size. Second, some patients did not undergo continuous follow-up and the interval between CT re-examination varied; therefore, our findings should be interpreted as descriptive and preliminary. Next a prospective multicenter study to observe the accurate temporal characteristics of lung cancer in a lobe affected by stable pulmonary tuberculosis is needed. Third, some cases didn’t undergo contrast enhanced CT-scans and dynamic enhanced scanning was not performed which precluded time-density curve analysis of nodules in the control group, which may have affected the results of the enhancement characteristics analysis. Fourth, the clinical utility of FDG PET/CT during the evaluation of lung nodules detected on CT need further evaluation. We hope that the preliminary results of this study will stimulate further researches in this area.

In conclusion, patients with stable pulmonary tuberculosis represent a group at risk for developing lung cancer and have to be controlled continuously. Regular CT re-examination is necessary and further prospective multicenter studies are needed to help guide the lung cancer screening of patients with stable pulmonary tuberculosis.
Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

Ethics statement

The studies involving human participants were reviewed and approved by Ethic Committee of the Xiangya Hospital of Central South University. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

Author contributions

HZ conceived and designed the research. KL, LL acquired the data. HZ, KL analyzed and interpreted the data. HZ, KL and JC performed statistical analysis. KL and YL drafted the manuscript. HZ made critical revision of the manuscript for important intellectual content. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by Natural Science Foundation of Hunan Province, China (2021JJ31131).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2022.868107/full#supplementary-material

References

1. World Health Organization. *Global tuberculosis report* (2020). Available at: https://apps.who.int/iris/handle/10665/336069 (Accessed March 10, 2021).

2. Cao M, Chen W. Epidemiology of lung cancer in China. *Thorac Cancer*. (2019) 10:3–7. doi: 10.1111/1759-7714.12916

3. Hong S, Mok Y, Jeon C, Jee SH, Samet JM. Tuberculosis, smoking and risk for lung cancer incidence and mortality. *Int J Cancer*. (2016) 139:2447–55. doi: 10.1002/ijc.30384

4. Ho JC, Leung C. Management of co-existent tuberculosis and lung cancer. *Lung Cancer*. (2018) 122:83–7. doi: 10.1016/j.lungcan.2018.05.030

5. World Health Organization. Systematic screening for active tuberculosis principles & recommendations (2013). Available at: https://www.who.int/tb/publications/Final_TB_Screening_guidelines.pdf (Accessed Sep 8, 2022).

6. Cui X, Han D A, Heuvelmans M, Du Y, Zhao Y, Zhang L, et al. Clinical characteristics and work-up of small to intermediate-sized pulmonary nodules in a Chinese dedicated cancer hospital. *Cancer Biol Med* (2020) 17:199–207. doi: 10.20892/issn.2095-3941.2019.0028

7. Bueno J, Landeras L, Chung JH. Updated fleischner society guidelines for managing incidental pulmonary nodules: Common questions and challenging scenarios. *Radiographics*. (2018) 38:1337–50. doi: 10.1148/radiographics.2018180017

8. Zhang M, Kono M. Solitary pulmonary nodules: Evaluation of blood flow patterns with dynamic CT. *Radiology*. (1997) 205:471–8. doi: 10.1148/radiology.205.2.9356631

9. ACoR. *Lung-screening reporting and data system (Lung-RADS)* version 1.1 (2019). Available at: https://www.acorr.org/-media/ACoR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf?la=en (Accessed Sep 08, 2018).

10. Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, et al. Treatment of drug-resistant tuberculosis. an official ATS/IDSA clinical practice guideline. *Am J Respir Crit Care* (2019) 200:e93–142. doi: 10.1164/rccm.201909-1874ST

11. Mehdi F, Fock-Yee C, Bourry D, Raffetin L, Bouchaud O, Brauner M, et al. Tuberculose pulmonaire : évolution radiologique des lésions broncho-pulmonaires en fin de traitement. *Rev Mal Respir* (2019) 36:22–30. doi: 10.1016/j.rmr.2018.08.005

12. MacMahon H, Naichich DP, Goo JM, Lee KS, Leung ANC, Mayo JR, et al. Guidelines for management of incidental pulmonary nodules detected on CT images: From the fleischner society 2017. *Radiology*. (2017) 284:228–43. doi: 10.1148/radiol.2017161659

13. Kim YI, Goo JM, Kim HY, Song JW, Im J. Coexisting bronchogenic carcinoma and pulmonary tuberculosis in the same lobe: Radiologic findings and clinical significance. *Korean J Radiol* (2001) 2:138. doi: 10.3348/kjr.2001.2.3.138

14. Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. *Lung Cancer*. (2012) 76:138–43. doi: 10.1016/j.lungcan.2011.11.012

15. Luong H, Li X, Yu X, Guan P, Yin Z, He Q, et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: A systematic review. *Int J Cancer*. (2009) 125:2936–44. doi: 10.1002/ijc.24636

16. Abdehadad H, Salehi M, Yaghoubi A, Aalami AH, Aalami F, Soleimanpour S. Previous pulmonary tuberculosis enhances the risk of lung cancer: Systematic reviews and meta-analysis. *Infect Dis-Nor*. (2022) 54:255–68. doi: 10.1080/23744235.2021.2060772

17. Auguste P, Tsvetkova A, Pink J, Court R, McCarthy N, Sutcliffe P, et al. Comparing interferon-gamma release assays with tuberculin skin test for identifying latent tuberculosis infection that progresses to active tuberculosis: Systematic review and meta-analysis. *BMC Infect Dis* (2017) 17:280. doi: 10.1186/s12879-017-2301-4

18. Yu Y, Liao C, Hsu W, Chen H, Liao W, Mao C, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: A population cohort study. *J Thorac Oncol* (2011) 6:327–3. doi: 10.1097/JTO.0b013e3181f464cc

Publisher note

This work was supported by Natural Science Foundation of Hunan Province, China (2021JJ31131).
19. Dacosta NA, Kinare SG. Association of lung carcinoma and tuberculosis. *J Postgrad Med* (1991) 37:185–9.

20. Bobba RK, Holly JS, Loy T, Perry MC. Scar carcinoma of the lung: A historical perspective. *Clin Lung Cancer*. (2011) 12:148–54. doi: 10.1016/j.cllc.2011.03.011

21. Wu C, Hu H, Pu C, Huang N, Shen H, Li C, et al. Pulmonary tuberculosis increases the risk of lung cancer. *Cancer-Am Cancer Soc* (2011) 117:618–24. doi: 10.1002/cncr.25616

22. Ob C, Roh Y, Lim D, Kong H, Cho H, Hwangbo B, et al. Pulmonary tuberculosis is associated with elevated risk of lung cancer in Korea: The nationwide cohort study. *J Cancer*. (2020) 11:1899–906. doi: 10.7150/jca.37022

23. Molina-Romero C, Arrieta O, Hernández-Pando R. Tuberculosis and lung cancer. *Salud Publica Mex* (2019) 61:286–91. doi: 10.21149/10090

24. Luo Y, Wu C, Wu W, Huang C, Su W, Tsai C, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. *J Thorac Oncol* (2012) 7:299–305. doi: 10.1097/JTO.0b013e318238dd3b

25. Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, et al. Tracking the evolution of non-Small-Cell lung cancer. *New Engl J Med* (2017) 376:2109–21. doi: 10.1056/NEJMoa1616288

26. Truong MT, Ko JP, Rossi SE, Rossi I, Viswanathan C, Bruzzi JF, et al. Update in the evaluation of the solitary pulmonary nodule. *Radiographics*. (2014) 34:1658–79. doi: 10.1148/rg.346130092

27. Jiang L, Situ D, Lin Y, Su X, Zheng Y, Zhang Y, et al. Clinical model to estimate the pretest probability of malignancy in patients with pulmonary focal ground-glass opacity. *Thorac Cancer*. (2013) 4:380–4. doi: 10.1111/1759-7714.12032

28. Patil SS, Godoy MCB, Sorensen IIL, Marom EM. Lung cancer imaging. *Semin Diagn Pathol* (2014) 31:293–305. doi: 10.1053/j.sdi.2014.06.007

29. Cui Y, Ma D, Liu W. Value of multiplanar reconstruction in MSCT in demonstrating the relationship between solitary pulmonary nodule and bronchus. *Clin Imag* (2009) 33:15–21. doi: 10.1016/j.clinimag.2008.06.028

30. Lee J, Lim JK, Seo H, Lee SY, Choe KJ, Yoo SS, et al. Clinical relevance of ground glass opacity in 105 patients with miliary tuberculosis. *Resp Med* (2014) 108:924–30. doi: 10.1016/j.rmed.2014.03.016

31. Ashizawa K, Matsuyama N, Okimoto T, Hayashi H, Takehashi T, Oka T, et al. Coexistence of lung cancer and tuberculoma in the same lesion: Demonstration by high resolution and contrast-enhanced dynamic CT. *Br J Radiology*. (2004) 77:959–62. doi: 10.1259/bjr/31864795

32. Hadique S, Jain P, Hadji Y, Baig A, Parker JE. Utility of FDG PET/CT for assessment of lung nodules identified during low dose computed tomography screening. *BMC Med Imaging*. (2020) 20:69. doi: 10.1186/s12880-020-00469-0

33. Priftakis D, Kizis S, Zamula A, Bomani J. Towards more accurate 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) imaging in active and latent tuberculosis. *Int J Infect Dis* (2020) 92:S85–90. doi: 10.1016/j.ijid.2020.02.017

34. Ankrah AO, van der Werf TS, de Vries EFJ, Diercks RAJO, Satheke M, Glasdemans AWJM. PET/CT imaging of mycobacterium tuberculosis infection. *Clin Trans Imaging*. (2016) 4:131–44. doi: 10.1007/s40336-016-0164-0